News

The acquisition is expected to be immediately accretive to Mallinckrodt’s fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in

With this approval in advanced cervical cancer, Avastin is approved in the US for the treatment of five distinct tumor types. The FDA approval is based on the

The company develops new therapies intended to improve outcomes in patients suffering from life-threatening diseases. La Jolla Research and Development vice-president and an inventor on the allowed patent

The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical

The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Following our recent European licensing agreement with Norgine, the

The study will focus on a medical syndrome, which according to a mounting tide of scientific research is having a debilitating effect on the health and vitality of

The issued patent claims cover systems for determining the activation state of more than one protein in a cell, where the system can utilize any detector, including cytometers

According to the company, the two patents (patent numbers are 8,771,732 and 8,765,175) will be Orange Book-listable. The two patents complement two additional issued formulation patents, as well

As part of the deal, Ligand will be receiving an up-front payment and is also eligible to get revenue from Captisol material sales, potential milestone payments and royalties